Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2904886rdf:typepubmed:Citationlld:pubmed
pubmed-article:2904886lifeskim:mentionsumls-concept:C0020094lld:lifeskim
pubmed-article:2904886lifeskim:mentionsumls-concept:C0019704lld:lifeskim
pubmed-article:2904886lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:2904886lifeskim:mentionsumls-concept:C2754997lld:lifeskim
pubmed-article:2904886lifeskim:mentionsumls-concept:C0020852lld:lifeskim
pubmed-article:2904886lifeskim:mentionsumls-concept:C0033105lld:lifeskim
pubmed-article:2904886lifeskim:mentionsumls-concept:C0205146lld:lifeskim
pubmed-article:2904886lifeskim:mentionsumls-concept:C0012764lld:lifeskim
pubmed-article:2904886lifeskim:mentionsumls-concept:C0521115lld:lifeskim
pubmed-article:2904886pubmed:issue4lld:pubmed
pubmed-article:2904886pubmed:dateCreated1989-2-7lld:pubmed
pubmed-article:2904886pubmed:abstractTextSerum samples collected from four groups of individuals in the Washington, D.C. area were examined for the presence of IgG and IgM classes of antibody reacting against HTLV-I and HIV-1. These four groups were: (1) healthy adults with negative premarital VDRL test for syphilis (n = 113), (2) miscellaneous common disease patients (n = 155), (3) drug abusers (n = 130), and (4) homosexual men (n = 187). The former two groups are considered to be low-risk groups, and the latter two, high-risk groups. The prevalence of IgG antibody on ELISA/Western blot tests for these groups were respectively: (1) 5.3%/1.8%, (2) 5.2%/1.9%, (3) 13.9%/4.6%, and (4) 4.3%/1.6% for HTLV-I, and (1) 2.7%/0.9%, (2) 4.5%/0%, (3) 12.3%/5.4%, and (4) 8.0%/5.9% for HIV-1. Instances of possible concomitant infection as shown by the presence of antibodies against both HTLV-I and HIV-1 were found only in the latter two high-risk groups, i.e. two (1.5%) in group (3), and three (1.6%) in group (4) as confirmed by both Western blot and immunofluorescence tests. Out of 97 sera collected from drug abusers in 1985-86 which had IgG antibody by Western blot test against HIV-1, 23 (23.7%) were HTLV-I antibody positive by ELISA test (Group 5), and 8 of these were confirmed by Western blot test. Among these 8 persons, IgM antibody against HTLV-I was found in 2, while that against HIV-1 was positive in 7 persons.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:2904886pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2904886pubmed:languageenglld:pubmed
pubmed-article:2904886pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2904886pubmed:citationSubsetIMlld:pubmed
pubmed-article:2904886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2904886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2904886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2904886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2904886pubmed:statusMEDLINElld:pubmed
pubmed-article:2904886pubmed:monthDeclld:pubmed
pubmed-article:2904886pubmed:issn0393-2990lld:pubmed
pubmed-article:2904886pubmed:authorpubmed-author:WangL CLClld:pubmed
pubmed-article:2904886pubmed:authorpubmed-author:ChangK SKSlld:pubmed
pubmed-article:2904886pubmed:authorpubmed-author:AlexanderSSlld:pubmed
pubmed-article:2904886pubmed:authorpubmed-author:TingR CRClld:pubmed
pubmed-article:2904886pubmed:authorpubmed-author:LogTTlld:pubmed
pubmed-article:2904886pubmed:authorpubmed-author:StricklandPPlld:pubmed
pubmed-article:2904886pubmed:authorpubmed-author:BodnerAAlld:pubmed
pubmed-article:2904886pubmed:authorpubmed-author:GaoC LCLlld:pubmed
pubmed-article:2904886pubmed:authorpubmed-author:KuoA FAFlld:pubmed
pubmed-article:2904886pubmed:issnTypePrintlld:pubmed
pubmed-article:2904886pubmed:volume4lld:pubmed
pubmed-article:2904886pubmed:ownerNLMlld:pubmed
pubmed-article:2904886pubmed:authorsCompleteYlld:pubmed
pubmed-article:2904886pubmed:pagination426-34lld:pubmed
pubmed-article:2904886pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:meshHeadingpubmed-meshheading:2904886-...lld:pubmed
pubmed-article:2904886pubmed:year1988lld:pubmed
pubmed-article:2904886pubmed:articleTitleConcomitant infection of HTLV-I and HIV-1: prevalence of IgG and IgM antibodies in Washington, D.C. area.lld:pubmed
pubmed-article:2904886pubmed:affiliationLaboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892.lld:pubmed
pubmed-article:2904886pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2904886lld:pubmed